Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

United States of America

FDA approves brodalumab for psoriasis with notice about risk of suicide

The US Food and Drug Administration (FDA) has approved an injectable biologic, brodalumab (Siliq), for psoriasis in adults that comes with a warning about the risk of suicide. 

The monoclonal antibody, which is indicated for moderate-to-severe disease, will receive a boxed warning and will only be available through a risk-evaluation mitigation-strategy programme, due to the treatment’s association with suicidal ideation and suicide events in clinical trials. 

During clinical trials, six patients treated with the drug committed suicide, a rate that was 3-4 times higher than that seen in other trials of biologics for psoriasis. The FDA said that although a causal link to suicide has not been established, the treatment should only be available through a restricted programme to try to minimise the risks. 

It requires prescribers to counsel patients on the risks, and they must sign a patient-prescriber agreement to receive the drug. Pharmacies must also be certified with the programme in order to dispense it. 

Brodalumab was developed under a collaboration agreement between Amgen and AstraZeneca. But in May 2015, Amgen abruptly ended their partnership on the drug, saying that the suicidal and behaviour events recorded during the trials would likely result in strict labelling requirements, limiting the potential patient population. Rights to the drug were subsequently licensed from AstraZeneca by New Jersey-based Valeant Pharmaceuticals. 

Brodalumab works by targeting the interleukin-17 receptor and thereby preventing an inflammatory cascade that leads to psoriasis plaques. The drug’s efficacy was explored in three randomised placebo-controlled trials involving more than 4,000 patients where, according to the pharmaceutical company Valeant, more than half of all patients had complete skin clearance of psoriasis within a year. 

The most common adverse reactions were headache, joint pain, fatigue, throat pain, and diarrhoea. 

In Europe the drug will be commercialised by LEO Pharma. A marketing authorisation application for brodalumab was submitted in the fourth quarter of 2015 to the European Medicines Agency and is currently under review. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202355

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • moderate to severe psoriasis

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.